These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31928732)

  • 21. Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease.
    Ryan P; Patel B; Makwana V; Jadhav HR; Kiefel M; Davey A; Reekie TA; Rudrawar S; Kassiou M
    ACS Chem Neurosci; 2018 Jul; 9(7):1530-1551. PubMed ID: 29782794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
    Golde TE
    J Neurochem; 2016 Oct; 139 Suppl 2(Suppl 2):224-236. PubMed ID: 27145445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
    Cho JE; Kim JR
    Recent Pat CNS Drug Discov; 2011 Sep; 6(3):222-33. PubMed ID: 21834780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yeast Model of Amyloid-β and Tau Aggregation in Alzheimer's Disease.
    Moosavi B; Mousavi B; Macreadie IG
    J Alzheimers Dis; 2015; 47(1):9-16. PubMed ID: 26402750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease.
    Mendonça CF; Kuras M; Nogueira FCS; Plá I; Hortobágyi T; Csiba L; Palkovits M; Renner É; Döme P; Marko-Varga G; Domont GB; Rezeli M
    Neurobiol Dis; 2019 Oct; 130():104509. PubMed ID: 31207390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease.
    Wang P; Ding K
    Protein Pept Lett; 2014; 21(10):1048-56. PubMed ID: 24975673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biophysical studies of protein misfolding and aggregation in
    Sinnige T; Stroobants K; Dobson CM; Vendruscolo M
    Q Rev Biophys; 2020 Jun; 49():e22. PubMed ID: 32493529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.
    West S; Bhugra P
    Br J Clin Pharmacol; 2015 Aug; 80(2):221-34. PubMed ID: 25753046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
    Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
    Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tau aggregation and its interplay with amyloid-β.
    Nisbet RM; Polanco JC; Ittner LM; Götz J
    Acta Neuropathol; 2015 Feb; 129(2):207-20. PubMed ID: 25492702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA in Alzheimer's disease revisited: implications for major neuropathological mechanisms.
    Dehghani R; Rahmani F; Rezaei N
    Rev Neurosci; 2018 Feb; 29(2):161-182. PubMed ID: 28941357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tau Protein Mediates APP Intracellular Domain (AICD)-Induced Alzheimer's-Like Pathological Features in Mice.
    Ghosal K; Fan Q; Dawson HN; Pimplikar SW
    PLoS One; 2016; 11(7):e0159435. PubMed ID: 27459671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD.
    Thal DR; Fändrich M
    Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324
    [No Abstract]   [Full Text] [Related]  

  • 37. Disrupting beta-amyloid aggregation for Alzheimer disease treatment.
    Estrada LD; Soto C
    Curr Top Med Chem; 2007; 7(1):115-26. PubMed ID: 17266599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.
    Roberson ED; Scearce-Levie K; Palop JJ; Yan F; Cheng IH; Wu T; Gerstein H; Yu GQ; Mucke L
    Science; 2007 May; 316(5825):750-4. PubMed ID: 17478722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Always around, never the same: pathways of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimer's disease.
    Hoozemans JJ; Chafekar SM; Baas F; Eikelenboom P; Scheper W
    Curr Med Chem; 2006; 13(22):2599-605. PubMed ID: 17017913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Implications of Autophagy in Alzheimer's Disease.
    Hamano T; Hayashi K; Shirafuji N; Nakamoto Y
    Curr Alzheimer Res; 2018; 15(14):1283-1296. PubMed ID: 30289076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.